Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands

Journal of Immunology

Volumn 167, Issue 7, 2001, Pages 3818-3828

  De Visser, K E ^a   Cordaro, T A ^a   Kessels, H W H G ^a   Tirion, F H ^a   Schumacher, T N M ^a   Kruisbeek, A M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; LIGAND; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION;

EID: 0035478689     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.7.3818     Document Type: Article

References (66)

1. Comparison of the T cell receptor on insulin-specific hybridomas from insulin transgenic and nontransgenic mice
2. Positive and negative thymocyte selection induced by different concentrations of a single peptide
3. Low avidity recognition of self-antigen by T cells permits escape from central tolerance
4. Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive T cells
5. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
6. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity
7. Thymic selection by a single MHC/peptide ligand: Autoreactive T cells are low-affinity cells
8. Tracing and characterization of the low-avidity self-specific T cell repertoire
9. + T lymphocytes that persist after peripheral tolerance to a self-antigen expressed in the pancreas
10. Activation of autoreactive T cells by peptides from human pathogens
11. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase
12. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
13. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high affinily, altered peptide ligand
14. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
15. Structural basis for T cell recognition of altered peptide ligands: A single T cell receptor can productively recognize a large conlinuum of related ligands
16. Selective activation of CD8 T cell affector functions by epitope variants of lymphocytic choriomeningitis virus glycoprotein
17. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells
18. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
19. Tolerance in TCR/cognate antigen double-transgenic mice mediated by incomplete thymic deletion and peripheral receptor downregulation
20. Phenotypic analysis of antigen-specific T lymphocytes
21. Systemic T cell expansion during localized viral infection
22. Studies in antibody response of mice to tumour inoculation
23. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3
24. Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells
25. Empty MHC class 1 molecules come out in the cold
26. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
27. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
28. CD40 activation in vivo overcomes peplide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
29. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
30. Interleukin-2: Inception, impact, and implications
31. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
32. High avidity CTLs for two self-antigens demonstrate superior in vivo and in vivo antitumor efficacy
33. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differnces in T cell receptor-dependent intracellular signaling
34. Induction of T-cell anergy by altered T cell-receptor ligand on live antigen-presenting cells
35. + T cells by a self-derived peptide
36. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand
37. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production
38. + memory T cells by viral variants
39. Selecting and maintaining a diverse T-cell repertoire
40. T-cell receptors from virus-specific cytotoxic T lymphocytes recognizing a single immunodominant nine-amino acid viral epitope show marked diversity
41. The MHC class 1-restricted T cell response to Sendai virus infection in C57BL/6 mice: A single immunodominant epitope elicits an extremety diverse repertoire of T cells
42. Structure of an αβ T cell receptor at 2.5 Å and its orientation in the TCR-MHC complex
43. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids
44. b-restricted peptides in class I binding and TCR triggering
45. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers or stimulatory ligands for autoreactive T cells
46. Endogenous myelin basic protein inactivates the high avidity T cell repertoire
47. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity
48. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen
49. Evidence for repression of IL-2 gene activation in anergic T cells
50. The role of clonal anergy in the avoidance of autoimmunity: Inactivation of autocrine growth without loss of effector function
51. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
52. + T cells
53. A molecular basis for how a single TCR interfaces multiple ligands
54. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor
55. Efficient T cell activation requires an optimal dwell-time of interaction btween the TCR and the pMHC complex
56. Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues
57. The stimulation of low-affinity nontolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope
58. An altered peptide ligand antagonizes antigen-specific T cells of patients with haman T lymphotropic virus type I-associated neurological disease
59. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC hinding through residue substitution
60. Heteroclitic immunization induces tumor immunity
61. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues
62. Amino-terminal alteration orthe HLA-A*020I-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity
63. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence
64. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: Implications for autoimmunity
65. + T cells with enhanced functional characteristics: Implications for more effective immunotherapy
66. b at 2.4 Å resolution: Implications for antigen-determinant selection